Pharvaris (PHVS) director Viviane Monges details initial equity holdings

Rhea-AI Filing Summary

Pharvaris N.V. director Viviane Monges has filed an initial statement of beneficial ownership detailing her equity position in the company. The filing lists several stock option awards on common stock with exercise prices between 8.0500 and 28.0000 per share and expiration dates running through 2036. It also shows direct ownership of 14,654 shares of common stock and notes restricted stock units granted under the company’s equity plan, including 5,500 RSUs from an award granted March 3, 2026 that will fully vest on March 3, 2027.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Monges Viviane

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/17/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,654(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	03/03/2027(2)	03/03/2036	Common Stock	16,500	$28	D
Stock Option (Right to Buy)	03/12/2026(2)	03/12/2035	Common Stock	15,000	$16.05	D
Stock Option (Right to Buy)	04/11/2025(2)	04/11/2034	Common Stock	14,000	$22.31	D
Stock Option (Right to Buy)	(3)	04/06/2033	Common Stock	21,000	$8.05	D
Stock Option (Right to Buy)	(4)	04/01/2032	Common Stock	17,500	$18.14	D
Stock Option (Right to Buy)	(5)	07/01/2031	Common Stock	35,000	$17.43	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

2. 100% of the option vest on the 12-month anniversary.

3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Vivian Monges	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Pharvaris (PHVS) Form 3 filed by Viviane Monges show?

The Form 3 shows director Viviane Monges’ initial equity holdings in Pharvaris N.V., including common shares, multiple stock option awards, and restricted stock units that vest over time as part of the company’s equity compensation program.

Did Viviane Monges buy or sell Pharvaris (PHVS) shares in this Form 3?

The Form 3 does not report any new purchases or sales. It is an initial ownership statement that lists existing common stock, stock options, and restricted stock units rather than recording new trading activity in Pharvaris shares.

What stock options does Viviane Monges report in Pharvaris (PHVS)?

Viviane Monges reports several stock option awards on Pharvaris common stock with exercise prices between 8.0500 and 28.0000 per share and expiration dates extending from 2031 to 2036, reflecting long-dated equity incentives as a company director.

How many Pharvaris (PHVS) common shares does Viviane Monges hold directly?

The filing shows Viviane Monges directly holding 14,654 shares of Pharvaris common stock. These are reported as non-derivative securities, separate from her stock option awards and restricted stock units granted under the company’s equity compensation plan.

What restricted stock units (RSUs) are disclosed for Viviane Monges at Pharvaris (PHVS)?

The footnotes state that her holdings include restricted stock units granted under Pharvaris’ equity plan, including 5,500 RSUs from an award dated March 3, 2026 that are scheduled to vest in full on March 3, 2027.

Are Viviane Monges’ Pharvaris (PHVS) options subject to vesting schedules?

Yes. Footnotes explain that certain option grants vest over time, including awards where 25% vested on specific past dates and the remaining shares vest in 1/48 monthly installments, and one grant where 100% vests on the 12‑month anniversary.